Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Deals Policy / Regulatory

US Blocks Asymchem’s Acquisition of Snapdragon Chemistry

Fineline Cube Sep 16, 2022

US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...

Company Drug

Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22

Fineline Cube Sep 16, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...

Policy / Regulatory

CDE Issues Guidelines for Anti-Tumor ADC Clinical Development

Fineline Cube Sep 16, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company

Eli Lilly Announces Global C-Suite Changes, New Leadership in China

Fineline Cube Sep 16, 2022

US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...

Company Policy / Regulatory

China’s Policy Shifts Medical Device Procurement Toward Domestic Products

Fineline Cube Sep 16, 2022

Local government policies in China have begun to direct public hospitals to prioritize the procurement...

Company

Antengene Expands to Australia with New Melbourne Office

Fineline Cube Sep 16, 2022

China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne,...

Company Deals

Great Bay Bio Completes USD 15M Pre-Series B Financing to Advance AI Bioprocessing Platforms

Fineline Cube Sep 15, 2022

Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD...

Company Deals

Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution

Fineline Cube Sep 15, 2022

China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with...

Company Deals

Suzhou Jade Biomedical Secures USD 10 Million Series B Financing

Fineline Cube Sep 15, 2022

China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B...

Company Deals

Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding

Fineline Cube Sep 15, 2022

Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...

Company Deals

Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center

Fineline Cube Sep 15, 2022

China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...

Company Deals

Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion

Fineline Cube Sep 15, 2022

Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...

Company Drug

Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance

Fineline Cube Sep 15, 2022

China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...

Company Deals

Bide Pharmatech Set for IPO on Shanghai’s STAR Market

Fineline Cube Sep 15, 2022

Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...

Drug Policy / Regulatory

NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Sep 15, 2022

The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...

Company Drug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

Fineline Cube Sep 15, 2022

Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...

Policy / Regulatory

Guangdong Launches Free HPV Vaccination Program for School-aged Girls

Fineline Cube Sep 15, 2022

Guangdong province has rolled out a free HPV vaccination program this month, aimed at improving...

Company Drug

Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis

Fineline Cube Sep 15, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...

Policy / Regulatory

Hubei Province Proposes National TCM Patent Medicine Procurement Alliance

Fineline Cube Sep 15, 2022

The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...

Company Drug

Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study

Fineline Cube Sep 15, 2022

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...

Posts pagination

1 … 670 671 672 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.